Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:GEMP Gemphire Therapeutics (GEMP) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsTrends About Gemphire Therapeutics Stock (NASDAQ:GEMP) 30 days 90 days 365 days Advanced Chart Ad Porter & CompanyRigged election? Porter Stansberry’s viral Breaking Point 2024 broadcast has now been by tens of thousands of Americans who finally understand the grim reality of our next election. With November 5 just around the corner, it’s imperative for your financial future that you read Porter’s message below now and then watch Breaking Point before it’s too late. Watch this video, it is being taken down Monday night Get Gemphire Therapeutics alerts:Sign Up Key Stats Today's Range$2.41▼$2.8450-Day Range$0.30▼$6.3852-Week Range$0.24▼$1.49Volume55,454 shsAverage Volume127,174 shsMarket Capitalization$37.63 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewGemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and nonalcoholic fatty liver disease (NAFLD/NASH). The company is developing gemcabene, a novel, once-daily, and oral therapy for dyslipidemia conditions where patients are unable to reach their lipid lowering goals, including patients already receiving maximally tolerated statin therapy. It also completed three Phase IIb clinical trials for gemcabene in homozygous familial hypercholesterolemia (HoFH) and hypercholesterolemia, including heterozygous familial hypercholesterolemic (HeFH) and atherosclerotic cardiovascular disease (ASCVD) patients on maximally tolerated statins, and severe hypertriglyceridemia (SHTG). The company was founded in 2008 and is headquartered in Livonia, Michigan.Read More… Rigged election? (Ad)Porter Stansberry’s viral Breaking Point 2024 broadcast has now been by tens of thousands of Americans who finally understand the grim reality of our next election. With November 5 just around the corner, it’s imperative for your financial future that you read Porter’s message below now and then watch Breaking Point before it’s too late. Watch this video, it is being taken down Monday night Receive GEMP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gemphire Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address GEMP Stock News HeadlinesHypertriglyceridemia Treatment Market Detect New Industry Opportumities 2023-2030May 11, 2023 | marketwatch.comNonalcoholic Steatohepatitis (NASH) Market 2023: Share and Growth Opportunities Forecast till 2030April 28, 2023 | marketwatch.comBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then.November 4, 2024 | Brownstone Research (Ad)2023-2031 Non-Alcoholic Steatohepatitis Market: Latest UpdatesApril 12, 2023 | marketwatch.com2023-2031 Non-Alcoholic Steatohepatitis Market: Latest UpdatesApril 12, 2023 | marketwatch.comNonalcoholic Steatohepatitis (NASH) Market Growth and Industry Insights till 2027March 29, 2023 | marketwatch.comGlobal Hypercholesterolemia Treatment Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2023-2030 By VMReportsMarch 26, 2023 | marketwatch.com2023 Hypertriglyceridemia Treatment Market Size, Growth | Global Industry Trends [2029]March 24, 2023 | marketwatch.comSee More Headlines GEMP Stock Analysis - Frequently Asked Questions How were Gemphire Therapeutics' earnings last quarter? Gemphire Therapeutics Inc (NASDAQ:GEMP) issued its quarterly earnings results on Friday, March, 15th. The company reported ($0.26) earnings per share for the quarter, topping analysts' consensus estimates of ($0.41) by $0.15. When did Gemphire Therapeutics IPO? Gemphire Therapeutics (GEMP) raised $30 million in an initial public offering on Friday, August 5th 2016. The company issued 3,000,000 shares at a price of $10.00 per share. Jefferies and RBC Capital Markets acted as the underwriters for the IPO and Canaccord Genuity and Roth Capital Partners were co-managers. What other stocks do shareholders of Gemphire Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Gemphire Therapeutics investors own include TG Therapeutics (TGTX), AcelRx Pharmaceuticals (ACRX), Pixelworks (PXLW), Clearside Biomedical (CLSD), Protalix BioTherapeutics (PLX), SCYNEXIS (SCYX) and Melinta Therapeutics (MLNT). Company Calendar Last Earnings3/15/2019Today11/04/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:GEMP CUSIPN/A CIK1638287 Webwww.gemphire.com Phone734-245-1700FaxN/AEmployees9Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-23,640,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-419.70% Return on Assets-173.05% Debt Debt-to-Equity RatioN/A Current Ratio0.67 Quick Ratio0.67 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.54 per share Price / Book4.94Miscellaneous Outstanding Shares14,872,000Free FloatN/AMarket Cap$39.71 million OptionableNot Optionable Beta2.82 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report This page (NASDAQ:GEMP) was last updated on 11/4/2024 by MarketBeat.com Staff From Our Partners2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfas...Investing Daily | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredA Totally New ‘Income Coin’Buckle up… Because this might shatter everything you thought you knew about "income trading." In fact, i...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gemphire Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Gemphire Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.